CClinicalTrials.gg
CompletedNCT03889522Updated Mar 16, 2026

The Influence of Non-Caloric Artificial Sweeteners on Youth With Type 1 Diabetes

An observational study in Type 1 Diabetes Mellitus, sponsored by Medical College of Wisconsin. Completed at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Medical College of Wisconsin · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
21
Ages
5 Years to 17 Years
Sex
All
01

Study summary

The investigators aim to further the understanding of environmental factors that may underlie variations in body composition seen in youth with Type 1 diabetes (T1D). Non-caloric artificial sweeteners, broadly consumed in many individuals with T1D, are a modifiable dietary factor that may be associated with negative health outcomes, particularly those relevant to the future risk of diabetes-related complications.

Investigators will measure body composition (the amount of fat and muscle in the body and where the fat is stored) using a bioelectrical impedance analysis machine and DEXA scanner. Blood will be drawn for the following labs: HbA1c, lipid panel, comprehensive metabolic panel and leptin. Participants will also answer questions about their diets and consumption of artificial sweeteners.

02

Conditions studied

  • Type 1 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 1

3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.

This study's enrollment of 21 is below the median of 120 across 748 observational studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 120 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Youth receiving care at the Children's Hospital of Wisconsin Diabetes Clinic.

Inclusion criteria

  1. Males and females aged 5-17 years with a clinical diagnosis of T1D of ≥ 6 months in duration
  2. BMI between the 5th and 95th percentile

Exclusion criteria

Exclusion Criteria:

  1. Presence of severe, active disease that requires the use of chronic medication, with the exception of well-controlled autoimmune thyroiditis/hypothyroidism or celiac disease that is well-controlled on a gluten free diet.
  2. Diabetes other than T1D
  3. Chronic illness known to affect glucose metabolism
  4. Psychiatric impairment, with the exception of well-controlled depression or anxiety, that will affect the ability to participate in the study
  5. Female participants of child-bearing age with reproductive potential must not be knowingly pregnant
  6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
21 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Diagnostic testBioelectrical Impedance Analysis

    BIA is a radiation-free and clinically accessible measure of body composition \[47, 49\]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.

    Also known as: BIA

  • Diagnostic testTotal Body Dual-energy X-ray Absorptiometry

    The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.

    Also known as: DXA

  • Diagnostic testBlood draw

    Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.

06

What researchers measure

Primary outcomes

  1. Quantify artificial sweetener consumption in youth with type 1 diabetes

    To quantify artificial sweetener consumption patterns in a cohort of youth with T1D through novel food frequency questionnaires (Non-caloric artificial sweetener Food Frequency Questionnaire for Food and the Non-caloric artificial sweetener Food Frequency Questionnaire for Beverages) and bioassay

    Time frame: Study Duration (1 year)

  2. Examine the relationship between artificial sweeteners and body composition

    To characterize the relationship between artificial sweetener consumption and measures of body composition, as measured by bioelectrical impedance analysis and DXA scanning, which provide information on the amount and distribution of fat and muscle in the body.

    Time frame: Study Duration (1 year)

  3. Examine the relationship between artificial sweeteners and kidney function

    To determine if the level of artificial sweeteners is associated with the serum creatinine level.

    Time frame: Study Duration (1 year)

  4. Examine the relationship between artificial sweeteners and liver function

    To determine if the level of artificial sweeteners is associated with serum AST and ALT levels

    Time frame: Study Duration (1 year)

  5. Examine the relationship between artificial sweeteners and lipid levels.

    To characterize the relationship between artificial sweetener consumption and metabolism and the levels of fasting lipids (triglyceride level, HDL, LDL, and total cholesterol).

    Time frame: Study Duration (1 year)

  6. Examine the relationship between artificial sweeteners and metabolism.

    To characterize the relationship between artificial sweetener consumption and metabolism, as measured by a leptin level.

    Time frame: Study Duration (1 year)

  7. Examine the relationship between artificial sweeteners and glycemic control

    To characterize the relationship between artificial sweetener consumption and measures of glycemic control, as determined by the presence or absence of microalbuminuria.

    Time frame: Study Duration (1 year)

  8. Examine the relationship between artificial sweeteners and glycemic control

    To characterize the relationship between artificial sweetener consumption and measures of glycemic control, as measured by total daily insulin dose.

    Time frame: Study Duration (1 year)

  9. Examine the relationship between artificial sweeteners and glycemic control

    To characterize the relationship between artificial sweetener consumption and measures of glycemic control, as measured by the percentage of time participants are within ideal range for blood glucose levels (as measured by glucose monitors.)

    Time frame: Study Duration (1 year)

  10. Examine the relationship between artificial sweeteners and hemoglobin A1c

    To characterize the relationship between artificial sweetener consumption and measures of glycemic control, as measured by serum HbA1c.

    Time frame: Study Duration (1 year)

07

Study locations

1 site
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03889522
Lead sponsor
Medical College of Wisconsin
Responsible party
Susanne Cabrera (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Mar 26, 2019
Start date
May 1, 2019
Primary completion
Feb 25, 2021
Completion
Feb 25, 2021
Last update
Mar 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion